GlassScriptPhysician profile
Loquintha D Vital
NPI 1790989630
$13,644.62
in general payments reported to CMS, 2019-2025
29 companies · $1,398 in 2025
The $1,398 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,765 · 2022: $2,606 · 2023: $1,747 · 2024: $1,130 · 2025: $1,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,990 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,989.80 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,672.95 | 2021-2025 | Minimed 780g, Minimed 770g |
| Novo Nordisk INC | $1,775.32 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $761.42 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $691.54 | 2021-2025 | Lokelma, Breztri, Farxiga |
| Abbvie INC. | $642.96 | 2021-2025 | |
| Amgen INC. | $451.81 | 2022-2025 | Krystexxa, Prolia, Evenity |
| Abbott Laboratories | $378.38 | 2022-2025 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $261.02 | 2021-2023 | Inspire |
| Mannkind Corporation | $197.62 | 2022-2024 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $194.60 | 2021-2022 | |
| Inari Medical, INC. | $166.80 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Sanofi-Aventis U.S. LLC | $163.70 | 2022-2024 | |
| Edwards Lifesciences Corporation | $154.04 | 2025 | Sapien 3 Ultra Resilia |
| Silk Road Medical, INC. | $150.00 | 2022 | |
| Nevro Corp. | $149.14 | 2023 | Senza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $121.27 | 2025 | Nuplazid |
| Xeris Pharmaceuticals, INC. | $113.10 | 2022-2023 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $111.78 | 2023 | Quviviq |
| Gilead Sciences, INC. | $103.18 | 2022 | |
| Boston Scientific Corporation | $101.41 | 2022 | |
| Heartflow, INC. | $61.17 | 2022 | |
| Endogastric Solutions, INC | $51.89 | 2023 | Esophyx |
| Dexcom, INC. | $27.76 | 2022 | |
| Verrica Pharmaceuticals INC. | $26.41 | 2024 | Ycanth |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.10 | 2021-2022 | |
| Organon LLC | $24.64 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.70 | 2021 | |
| Glaxosmithkline, LLC. | $20.97 | 2023 | Bexsero, Pediarix |
| Pfizer INC. | $19.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loquintha Vital listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.